Commentary

Interaction Between Adalimumab With Concurrent Pregabalin and Duloxetine Administration in a Psoriasis Patient With Diabetic Peripheral Neuropathy [letter]

Cutis. 2011 May;87(5):249,250
By
Wu JJ
Fleming KF
Author and Disclosure Information

No abstract available.
PDF Download

 

Recommended Reading

Belimumab's FDA Approval Marks New Lupus-Treatment Era
MDedge Dermatology
Sildenafil Reduces Attack Frequency in Raynaud's
MDedge Dermatology
SDEF: Consider Potential Risks of Newly Approved Therapeutics
MDedge Dermatology
SDEF: Psoriasis Comorbidities Carry Implications for Disease Management
MDedge Dermatology
Biologics Tied to Greater Risk of Adverse Events
MDedge Dermatology
Psoriasis Linked With 6% Higher Cardiovascular Disease Risk
MDedge Dermatology
Heart Involvement in Systemic Sclerosis Underappreciated
MDedge Dermatology
Study: Scleroderma Survival Improving
MDedge Dermatology
Cancer Risk Greater in Treated RA Patients Than in General Population
MDedge Dermatology
Ask the Expert: Scleroderma Mimics
MDedge Dermatology